Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1994 Jan 22;308(6923):235–246.

Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration.

PMCID: PMC2539330  PMID: 8054013

Abstract

OBJECTIVE--To determine the efficacy of antiplatelet therapy as prophylaxis against deep venous thrombosis or pulmonary embolism in surgical and high risk medical patients. DESIGN--Overviews of all randomised trials of antiplatelet therapy that could have been available by March 1990 and in which deep venous thrombosis was assessed systematically. SETTING--53 trials (total 8400 patients) of an average of two weeks of antiplatelet therapy versus control in general or orthopaedic surgery; nine trials (600 patients) of antiplatelet therapy versus control in other types of immobility; 18 trials (1000 patients) of one antiplatelet regimen versus another. RESULTS--Overall, a few weeks of antiplatelet therapy produced a highly significant (2P < 0.00001) reduction in deep venous thrombosis. 25% of patients allocated antiplatelet therapy versus 34% of appropriately adjusted controls had deep venous thrombosis detected by systematic fibrinogen scanning or venography, representing prevention in about 90 patients per 1000 allocated antiplatelet therapy. There was an even greater proportional reduction in pulmonary embolism: such emboli were detected among 47 (1.0%) antiplatelet allocated patients versus an adjusted control total of 129 (2.7%), representing prevention among about 17 patients per 1000 treated (2P < 0.00001). In analyses confined to surgical trials, the proportional reductions were similar and separately significant for nonfatal pulmonary embolism (0.7% antiplatelet therapy v 1.8% control; 2P < 0.00001) and for deaths attributed to pulmonary embolism (0.2% v 0.9%; 2P = 0.0001). There was a slight but non-significant excess of deaths from other causes (1.0% v 0.7%), which made the difference in total mortality nonsignificant, though still favourable (1.2% v 1.5%). Information on adding antiplatelet therapy to heparin was limited but, at least for pulmonary embolism, suggested more protection from the combination than from heparin alone. The proportional reduction in the odds of suffering a deep venous thrombosis was roughly the same in patients having general surgery, traumatic orthopaedic surgery, and elective orthopaedic surgery (and in medical patients who were at increased risk of thromboembolism). For pulmonary embolism the numbers affected were smaller, but again the reductions were highly significant both in general surgery (16 (0.5%) v 58 (1.7%) pulmonary emboli; 2P < 0.0001) and in orthopaedic surgery (28 (2.7%) v 63 (6.1%) pulmonary emboli; 2P < 0.0002). CONCLUSION--It had previously been supposed that antiplatelet therapy did not influence venous thromboembolism, and many surgeons and physicians do not use it routinely for thromboprophylaxis, even for patients who are at substantial risk of deep venous thrombosis or pulmonary embolism. These results indicate that antiplatelet therapy--either alone or, for greater effect, in addition to other proved forms of thromboprophylaxis (such as subcutaneous heparin)--should be considered.

Full text

PDF
235

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfaro M. J., Páramo J. A., Rocha E. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine. Thromb Haemost. 1986 Aug 20;56(1):53–56. [PubMed] [Google Scholar]
  2. Bergqvist D., Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg. 1985 Feb;72(2):105–108. doi: 10.1002/bjs.1800720211. [DOI] [PubMed] [Google Scholar]
  3. Browse N. L., Hall J. H. Effect of dipyridamole on the incidence of clinically detectable deep-vein thrombosis. Lancet. 1969 Oct 4;2(7623):718–720. doi: 10.1016/s0140-6736(69)90429-2. [DOI] [PubMed] [Google Scholar]
  4. Carter A. E., Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J. 1974 Jul 13;3(5923):94–95. doi: 10.1136/bmj.3.5923.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chrisman O. D., Snook G. A., Wilson T. C., Short J. Y. Prevention of venous thromboembolism by administration of hydroxychloroquine. A preliminary report. J Bone Joint Surg Am. 1976 Oct;58(7):918–920. [PubMed] [Google Scholar]
  6. Clagett G. P., Anderson F. A., Jr, Levine M. N., Salzman E. W., Wheeler H. B. Prevention of venous thromboembolism. Chest. 1992 Oct;102(4 Suppl):391S–407S. doi: 10.1378/chest.102.4_supplement.391s. [DOI] [PubMed] [Google Scholar]
  7. Clagett G. P., Schneider P., Rosoff C. B., Salzman E. W. The influence of aspirin on postoperative platelet kinetics and venous thrombosis. Surgery. 1975 Jan;77(1):61–74. [PubMed] [Google Scholar]
  8. Collins R., Gray R., Godwin J., Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med. 1987 Apr-May;6(3):245–254. doi: 10.1002/sim.4780060308. [DOI] [PubMed] [Google Scholar]
  9. Collins R., Scrimgeour A., Yusuf S., Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988 May 5;318(18):1162–1173. doi: 10.1056/NEJM198805053181805. [DOI] [PubMed] [Google Scholar]
  10. Cooke E. D., Dawson M. H., Ibbotson R. M., Bowcock S. A., Ainsworth M. E., Pilcher M. F. Failure of orally administered hydroxychloroquine sulphate to prevent venous thromboembolism following elective hip operations. J Bone Joint Surg Am. 1977 Jun;59(4):496–500. [PubMed] [Google Scholar]
  11. Dechavanne M., Ville D., Viala J. J., Kher A., Faivre J., Pousset M. B., Dejour H. Controlled trial of platelet anti-aggregating agents and subcutaneous heparin in prevention of postoperative deep vein thrombosis in high risk patients. Haemostasis. 1975;4(2):94–100. doi: 10.1159/000214092. [DOI] [PubMed] [Google Scholar]
  12. Flicoteaux H., Kher A., Jean N., Blery M., Judet T., Honnart F., Pasteyer J. Comparision of low dose heparin and low dose heparin combined with aspirin in prevention of deep vein thrombosis after total hip replacement. Pathol Biol (Paris) 1977 Dec;25 (Suppl):55–58. [PubMed] [Google Scholar]
  13. Gent M., Roberts R. S. A meta-analysis of the studies of dihydroergotamine plus heparin in the prophylaxis of deep vein thrombosis. Chest. 1986 May;89(5 Suppl):396S–400S. doi: 10.1378/chest.89.5_supplement.396s. [DOI] [PubMed] [Google Scholar]
  14. Goldhaber S. Z., Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism. Report of the WHO/International Society and Federation of Cardiology Task Force. JAMA. 1992 Oct 7;268(13):1727–1733. [PubMed] [Google Scholar]
  15. Grandi A., Parodi J. C., Rotondaro D., Soffer F., Alle E. Prevención de la flebotrombosis post-operatoria. Medicina (B Aires) 1979 May-Jun;39(3):379–383. [PubMed] [Google Scholar]
  16. Green D., Rossi E. C., Yao J. S., Flinn W. R., Spies S. M. Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. Paraplegia. 1982 Aug;20(4):227–234. doi: 10.1038/sc.1982.41. [DOI] [PubMed] [Google Scholar]
  17. Hansen E. H., Jessing P., Lindewald H., Ostergaard P., Olesen T., Malver E. I. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine. J Bone Joint Surg Am. 1976 Dec;58(8):1089–1093. [PubMed] [Google Scholar]
  18. Harris W. H., Athanasoulis C. A., Waltman A. C., Salzman E. W. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg Am. 1985 Jan;67(1):57–62. [PubMed] [Google Scholar]
  19. Harris W. H., Salzman E. W., Athanasoulis C. A., Waltman A. C., DeSanctis R. W. Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977 Dec 8;297(23):1246–1249. doi: 10.1056/NEJM197712082972302. [DOI] [PubMed] [Google Scholar]
  20. Hartung B., Schreiber U., Rödiger H. Testung des Thrombozytenaggregationshemmers MICRISTIN auf seine Wirksamkeit als Thromboembolieprophylaktikum in der postoperativen Phase nach chirurgischen Eingriffen. Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):810–827. [PubMed] [Google Scholar]
  21. Huber O., Bounameaux H., Borst F., Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg. 1992 Mar;127(3):310–313. doi: 10.1001/archsurg.1992.01420030076014. [DOI] [PubMed] [Google Scholar]
  22. Hume M., Bierbaum B., Kuriakose T. X., Surprenant J. Prevention of postoperative thrombosis by aspirin. Am J Surg. 1977 Apr;133(4):420–422. doi: 10.1016/0002-9610(77)90125-8. [DOI] [PubMed] [Google Scholar]
  23. Hume M., Donaldson W. R., Suprenant J. Sex, aspirin, and venous thrombosis. Orthop Clin North Am. 1978 Jul;9(3):761–767. [PubMed] [Google Scholar]
  24. Johansson E., Forsberg K., Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis. 1981;10(2):89–96. doi: 10.1159/000214391. [DOI] [PubMed] [Google Scholar]
  25. Kakkar V. V. Prevention of venous thromboembolism. Clin Haematol. 1981 Jun;10(2):543–582. [PubMed] [Google Scholar]
  26. Kerrigan G. N., Buchanan M. R., Cade J. F., Regoeczi E., Hirsh J. Investigation of the mechanism of false positive 125I-labelled fibrinogen scans. Br J Haematol. 1974 Mar;26(3):469–473. doi: 10.1111/j.1365-2141.1974.tb00488.x. [DOI] [PubMed] [Google Scholar]
  27. Lensing A. W., Hirsh J. 125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost. 1993 Jan 11;69(1):2–7. [PubMed] [Google Scholar]
  28. Lieberman J., Winter B., Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest. 1986 Mar;89(3):370–373. doi: 10.1378/chest.89.3.370. [DOI] [PubMed] [Google Scholar]
  29. Loew D., Brücke P., Simma W., Vinazzer H., Dienstl E., Boehme K. Acetylsalicylic acid, low dose heparin, and a combination of both substances in the prevention of postoperative thromboembolism. A double blind study. Thromb Res. 1977 Jul;11(1):81–86. doi: 10.1016/0049-3848(77)90070-6. [DOI] [PubMed] [Google Scholar]
  30. Loew D., Wellmer H. K., Baer U., Merguet H., Rumpf P., Petersen H., Bromig G., Persch W. F., Marx F. J., von Bary S. M. Postoperative Thrombembolie-Prophylaxe mit Acetylsalicylsäure. Dtsch Med Wochenschr. 1974 Mar 22;99(12):565–572. doi: 10.1055/s-0028-1107803. [DOI] [PubMed] [Google Scholar]
  31. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  32. McKenna R., Galante J., Bachmann F., Wallace D. L., Kaushal P. S., Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J. 1980 Feb 23;280(6213):514–517. doi: 10.1136/bmj.280.6213.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Morris G. K., Mitchell J. R. Preventing venous thromboembolism in elderly patients with hip fractures: studies of low-dose heparin, dipyridamole, aspirin, and flurbiprofen. Br Med J. 1977 Feb 26;1(6060):535–537. doi: 10.1136/bmj.1.6060.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Müller T. H., Su C. A., Weisenberger H., Brickl R., Nehmiz G., Eisert W. G. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol. 1990 Aug;30(2):179–186. doi: 10.1111/j.1365-2125.1990.tb03763.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Plante J., Boneu B., Vaysse C., Barret A., Gouzi M., Bierme R. Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. Thromb Res. 1979 Feb-Mar;14(2-3):399–403. doi: 10.1016/0049-3848(79)90248-2. [DOI] [PubMed] [Google Scholar]
  36. Renney J. T., O'Sullivan E. F., Burke P. F. Prevention of postoperative deep vein thrombosis with dipyridamole and aspirin. Br Med J. 1976 Apr 24;1(6016):992–994. doi: 10.1136/bmj.1.6016.992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Saniabadi A. R., Tomiak R. H., Lowe G. D., Barbenel J. C., Forbes C. D. Dipyridamole inhibits red cell-induced platelet activation. Atherosclerosis. 1989 Apr;76(2-3):149–154. doi: 10.1016/0021-9150(89)90098-1. [DOI] [PubMed] [Google Scholar]
  38. Sautter R. D., Koch E. L., Myers W. O., Ray J. R., 3rd, Mazza J. J., Larson D. E., Chen H. M., Milbauer J. P., Treuhaft P. S., Plotka E. D. Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement. JAMA. 1983 Nov 18;250(19):2649–2654. [PubMed] [Google Scholar]
  39. Schreiber U., Hartung B. Postoperative Thromboembolieprophylaxe bei Patienten mit allgemeinchirurgischen Operationen. Zentralbl Chir. 1979;104(18):1214–1220. [PubMed] [Google Scholar]
  40. Scurr J. H., Coleridge-Smith P. D., Hasty J. H. Deep venous thrombosis: a continuing problem. BMJ. 1988 Jul 2;297(6640):28–28. doi: 10.1136/bmj.297.6640.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet. 1980 Dec 20;2(8208-8209):1328–1329. doi: 10.1016/s0140-6736(80)92396-x. [DOI] [PubMed] [Google Scholar]
  42. Turpie A. G., Gent M., Doyle D. J., Saerens E., de Boer A. C., Talbot C., McNamee J., Hirsh J. An evaluation of suloctidil in the prevention of deep vein thrombosis in neurosurgical patients. Thromb Res. 1985 Jul 15;39(2):173–181. doi: 10.1016/0049-3848(85)90105-7. [DOI] [PubMed] [Google Scholar]
  43. Veth G., Meuwissen O. J., van Houwelingen H. C., Sixma J. J. Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone. Thromb Haemost. 1985 Oct 30;54(3):570–573. [PubMed] [Google Scholar]
  44. Vinazzer H., Loew D., Simma W., Brücke P. Prophylaxis of postoperative thromboembolism by low dose heparin and by acetylsalicylic acid given simultaneously. A double blind study. Thromb Res. 1980 Jan 1;17(1-2):177–184. doi: 10.1016/0049-3848(80)90304-7. [DOI] [PubMed] [Google Scholar]
  45. Wood E. H., Prentice C. R., McGrouther D. A., Sinclair J., McNicol G. P. Trial of aspirin and RA 233 in prevention of post-operative deep vein thrombosis. Thromb Diath Haemorrh. 1973 Sep 15;30(1):18–24. [PubMed] [Google Scholar]
  46. Zekert F., Hofbauer F., Mühlbacher F. Thromboembolie-Prophylaxe in der Abdominalchirurgie. Vergleich von niedrig dosiertem Heparin, Azetylsalizylsäure und deren Kombination. MMW Munch Med Wochenschr. 1980 Oct 24;122(43):1495–1498. [PubMed] [Google Scholar]
  47. Zekert F., Kohn P., Vormittag E., Poigenfürst J., Thien M. Thromboembolieprophylaxe mit Acetylsalicylsäure bei Operationen wegen jüfgelenksnaher Frakturen. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed. 1974 Mar;77(3):97–110. [PubMed] [Google Scholar]
  48. Zekert F., Schemper M., Neumann K. Acetylsalicylic acid in combination with dihydroergotamine for preventing thromboembolism. Haemostasis. 1982;11(3):149–153. doi: 10.1159/000214655. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES